Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease

Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease

Background/AimsThis was a Phase 2 study (NCT02015793) to evaluate the pharmacokinetics, safety, and efficacy of adalimumab in Chinese patients with Crohn's disease (CD).MethodsThirty, adult Chinese patients with CD (CD Activity Index [CDAI] 220–450; high-sensitivity [hs]-C-reactive protein [CRP...

Full description

Bibliographic Details
Main Authors: Kai-Chun Wu, Zhi Hua Ran, Xiang Gao, Minhu Chen, Jie Zhong, Jian-Qiu Sheng, Michael A Kamm, Simon Travis, Kori Wallace, Nael M Mostafa, Marisa Shapiro, Yao Li, Roopal B Thakkar, Anne M Robinson
Format: Article
Language:English
Published: Korean Association for the Study of Intestinal Diseases 2016-04-01
Series:Intestinal Research
Subjects:
Crohn disease
Anti-tumor necrosis factor
Adalimumab
Online Access:http://www.irjournal.org/upload/pdf/ir-14-152.pdf

Internet

http://www.irjournal.org/upload/pdf/ir-14-152.pdf

Similar Items